创伤后抗Xa峰值水平与静脉血栓栓塞症的关系
本文为2015年1月至2017年3月194例创伤ICU患者的回顾性综述。所有患者初始接受依诺肝素30 mg每日两次皮下注射并联合机械装置进行血栓预防,每第三剂后检测抗Xa峰值,剂量上调至最大60 mg每日两次皮下注射,直至抗Xa峰值达0.2-0.4 IU/mL。总体VTE发生率为7.2%(n=14),其中深静脉血栓10例、肺栓塞5例,1例同时发生深静脉血栓和肺栓塞。达到预防性抗Xa水平者与未达到者的VTE(6.9% vs 7.6%,p=0.841)、深静脉血栓(3.9% vs 6.5%,p=0.413)、肺栓塞(3.9% vs 1.1%,p=0.213)发生率均无差异。
要点
- 194例创伤ICU患者中,抗Xa峰值达0.2-0.4 IU/mL者与未达者VTE发生率无差异(6.9% vs 7.6%,p=0.841)。
- 总体VTE发生率为7.2%(n=14),其中深静脉血栓10例、肺栓塞5例,1例同时发生深静脉血栓和肺栓塞。
- VTE诊断中位时间为14(7-17)天;诊断VTE者中50.0%(n=7)从未达到0.2-0.4 IU/mL抗Xa水平。
- 初始即达预防性抗Xa水平者64例(33.0%),后续追加达标38例(19.6%),总达标率52.6%(n=102)。
- 部分创伤患者尽管反复给药超过10天,仍未达到0.2-0.4 IU/mL的抗Xa峰值水平。
适用人群与场景
- 2015年1月至2017年3月期间收治的194例钝性或穿透性创伤ICU患者。
诊断标准与关键阈值
- 抗Xa峰值目标范围为0.2-0.4 IU/mL,于每第三剂依诺肝素后抽血检测。
- Greenfield风险评估量表评分为9 ± 4,损伤严重度评分为23 ± 14。
处置流程与药物剂量
- 所有患者初始接受依诺肝素30 mg每日两次皮下注射,并联合机械装置进行血栓预防。
- 依诺肝素剂量上调至最大60 mg每日两次皮下注射,直至抗Xa峰值达0.2-0.4 IU/mL。
- 每第三剂依诺肝素后检测抗Xa峰值水平。
研究设计与关键结果
- 研究类型为回顾性综述,样本量194例,人群为创伤ICU患者,干预为依诺肝素剂量调整至抗Xa峰值0.2-0.4 IU/mL,对照为未达该水平者。
- 总体VTE发生率为7.2%(n=14),其中深静脉血栓10例、肺栓塞5例,1例同时发生深静脉血栓和肺栓塞。
- VTE诊断中位时间为14(7-17)天。
- 诊断VTE者中50.0%(n=7)从未达到0.2-0.4 IU/mL抗Xa水平,42.8%(n=6)在达到该水平后被诊断为VTE。
- 初始即达预防性抗Xa水平者64例(33.0%),后续追加达标38例(19.6%),总达标率52.6%(n=102)。
- 达标者与未达标者VTE发生率无差异(6.9% vs 7.6%,p=0.841),深静脉血栓(3.9% vs 6.5%,p=0.413)和肺栓塞(3.9% vs 1.1%,p=0.213)发生率亦无差异。
- 住院时长为19(11-38)天。
证据类型、等级与局限
- 证据类型为治疗性研究,证据等级为level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者假设达到0.2-0.4 IU/mL抗Xa水平会降低创伤后VTE发生率,但本研究结果显示达标者与未达标者VTE发生率无差异。
- 部分创伤患者尽管反复给药超过10天,仍未达到0.2-0.4 IU/mL的抗Xa峰值水平。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: No previous studies have established the optimal antifactor Xa (anti-Xa) level to guide thromboprophylaxis (TPX) dosing with enoxaparin in trauma patients. We hypothesize that achieving 0.2-0.4 IU/mL anti-Xa will decrease venous thromboembolism (VTE) rates after trauma.
METHODS: This was a retrospective review of 194 intensive care unit patients sustaining blunt or penetrating trauma from January 2015 to March 2017. All received initial enoxaparin (30 mg BID subcutaneous) and mechanical devices for TPX. Peak anti-Xa levels were drawn after each third dose. The enoxaparin dose was adjusted up to a maximum of 60 mg BID subcutaneous until a peak level of 0.2-0.4 IU/mL was achieved. Data are expressed as mean ± SD if parametric or median (IQR) if not.
RESULTS: The Greenfield Risk Assessment Profile score was 9 ± 4, Injury Severity Score 23 ± 14, and hospital length of stay 19 (11-38) days. The overall VTE rate was 7.2% (n = 14), with 10 deep venous thromboses (DVT) and 5 pulmonary emboli (PE). One patient had both a DVT and PE. The median time to VTE diagnosis was 14 (7-17) days. In those diagnosed with a VTE, 50.0% (n = 7) never reached 0.2-0.4 IU/mL anti-Xa and 42.8% (n = 6) were diagnosed with a VTE after achieving these levels. Prophylactic levels were achieved initially in 64 (33.0%) patients, and achieved later in 38 (19.6%) additional patients, giving an overall prophylactic rate of 52.6% (n = 102). There were no differences in VTE (6.9% vs. 7.6%, p = 0.841), DVT (3.9% vs. 6.5%, p = 0.413), or PE (3.9% vs. 1.1%, p = 0.213) rates between those who became prophylactic and those who did not.
CONCLUSIONS: There was no difference in VTE incidence between those achieving anti-Xa peak levels of 0.2-0.4 IU/mL and those who did not. Furthermore, these levels were never achieved in some trauma patients despite repeated dosing over a >10-day period.
LEVEL OF EVIDENCE: Therapeutic study, level IV.
参考来源
- Karcutskie CA, Dharmaraja A, Patel J, et al. Relation of antifactor-Xa peak levels and venous thromboembolism after trauma. J Trauma Acute Care Surg. 2017. PMID: 29190255. doi:10.1097/TA.0000000000001663
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。